Member Info for draft

go read the RNSSs - all contradict each other. If EMEX was such a good deal then y have box lost HALF the revenue!

Flitcrofts also a director of SVS securities and that has had a very good year, look at accounts at companies house. but flitcroft very silent at Box generally

Hope BOX arent lying Boxhill's payments division has a very healthy sale pipeline with a number of significant transactions in progress which are expected to close in the coming few weeks which will yield revenues well in excess of the entire business H1 revenues. what transaction they doing thats suddenyl going to give them more than 500k revenue. And no explanation of where the 500k lost revenue even came from?

was $52.5billion - GL does a deal with them this will skyrocket.

If Iclaprim goes blockbuster it will have billions of sales and if GL secures a big pharma you can expect serious fireworks here. Do you think Merril Lynch are mad taking 7% Just a sample of 2016 antibiotic sales - the key for Iclaprim will be Marketing and advertising to hospitals by GL - and he clearly has this in hand from the presentation he did. SALES 15. Advair /Seretide (fluticasone and salmeterol) 2016 sales: $4.325 billion #13. Lyrica� (pregabalin) 2016 sales:�$4.966 billion� #6. Revlimid� (lenalidomide) 2016 sales:�$6.974 billion #1. Humira� (adalimumab) 2016 sales:�$16.078 billion

The global cystic fibrosis therapeutics market is expected to reach USD 13.9 billion by 2025, Motif Bio PLC said Tuesday it has received a funding award from the Cystic Fibrosis Foundation to advance the development of iclaprim for the treatment of lung infections in patients with cystic fibrosis. "Patients with cystic fibrosis, especially in the later stages of lung disease, are often infected with multidrug resistant bacteria that severely limit treatment options. The grant will advance the work we are doing to further elucidate iclaprim's ability to inhibit the most problematic bacteria, including multidrug resistant bacteria, that are common in patients with cystic fibrosis," said Motif Bio's Chief Medical Officer David Huang. The clinical-stage biopharmaceutical company said iclaprim has been studied in an animal model of chronic pulmonary methicillin resistant Staphylococcus aureus infection, which mimics the pathophysiology observed in the lungs of patients with cystic fibrosis.Iclaprim has been granted orphan drug designation by the US Food & Drug Administration for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis.

im also in Ixico which does medical imaging in North America- got a market cap of 10million, fbdu shoudl easily walk to �10million

I like the way you post, you dont resort to rudness etc . good on you.

any new updates on that front?

wiered how the updates contradict each other

Cant be much progress since the last November update surely? 03 Jan 2018 Appointment of Mr John Michael Botros as a director on 28 December 2017 View PDF ( Appointment of Mr John Michael Botros as a director on 28 December 2017 - link opens in a new window ) (2 pages) 03 Jan 2018 Termination of appointment of Philip Ian Jackson as a director on 28 December 2017

i might as well write this all off now buddy. Im joking - anyway looks like BOTROS is now director of EMEX TECHNOLOGIES and they got PHIL off the directots thing. why would anyone bother to use EMEXPAY and EMEXGO anyway - i dont get it. I think Jim ROse has had enough of all this *******s and will have made his voice heared - we maybe in for a decent update.

mr calm - when did you arrive - this is bound to go wrong now innit mate. FLIP. oh f u k

good analysis, lots of newsflow to come!

this is really going to pay off if we get farm in

we will all be asking where the 1mill placing cash went

is big player be laughing here

I'm staying in for the big one now.

they got close to getting the preferred ceo. there's 1 guy they really want. think if ceo news comes next should be a nice move up.

yeah there's no stock. and its going to be a huge recovery play i think.